Author of

• 25938

  +

  P2.01 - Advanced NSCLC (Not CME Accredited Session) (ID 950)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall

  • 26848

    +

    P2.01-49 - Comparision of Radiotheraphy Concurrent Weekly Treatment in Locally Advanced Unresectable Non Small Cell Lung Cancer (ID 13171)

    16:45 - 18:00  |  Author(s): Nadiye Akdeniz
    • Abstract
    • Slides

    Background
    

    Despite concurrent chemoradiotheraphy is standard treatment of unresectable locally advanced non small cell lung cancer (NSCLC),optimal chemotheraphy regimen is still inconclusive. Radiotheraphy concurrent weekly chemotheraphy has been studying and due to less toxicity it is preferred. In this study, we aimed to compare two weekly different regimens in terms of outcome and toxicity .

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    We screened retrospectively 142 patients with stage III, locally advanced unresectable NSCLC, treated with radiotheraphy concurrent weekly platinum-paclitaxel ( PP) or platinum-docetaxel (PD ) between 2006 and 2017 years.Age, sex, stage, histologic subtype, response rates, survival and toxicity were analyzed. In RT concurrently PP arm 50 mg/m² paclitaxel and 20 mg/m² cisplatin or carboplatin AUC 2; in PD arm 20 mg/m² dosetaxel and 20 mg/m² cisplatin applied. Radiotheraphy applied as weekly 5 fraction/ 60-66 Gy. Treatment response classified progression and clinically responsive which consist of stable response (SR), complete response(CR) and partial response(PR).

    4c3880bb027f159e801041b1021e88e8 Result
    

    One hundred thirty one (92,3%) patients were man and median age was 62 (25-79). Histologic subtype was squamous cell carcinoma in 77 (54.2%) patients. At diagnosis 53 patients (37,3%) were stage IIIA, 89 (62,7%) patients were stage IIIB and IIIC. There were 102 patients in DP arm whereas 40 patients were in PP arm. Age, gender, stage and histologic subtypes were similar in both groups.There were no statistically significant in clinically response rates between two group (PD 96,1% vs PP 90% , p = 0.15) . Median overall survival (OS) was higher in PP arm than PD arm ( 29 vs 14,4 months ,p=0,018). Progression free survival (PFS) were same in both arms (15,6 vs 15,4 months p=0,522).There were no statistically significant in mucositis and eosophitis( 90% vs 80 %, p=0,418) and vomiting (10% vs 8,8%, p=0,931) in both arms. In PP arm neutropenia (p=0,000) and thrombocytopenia rates were higher (p=0,021). Pulmonary toxicity (p=0,053) and nausea (p=0,056) was higher in PP arm, which is closed to statistical significance. Although deaths due to treatment toxicity were not detected ,progression and other reason related death were more common in PD arm (p<0,001).

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    In our study, despite clinical response and PFS were same in both radiotheraphy concurrent regimens in locally advanced unresectable NSCLC, OS was higher in PP arm. There are few study compared this two arms, which show no OS differences. Although it must be supported by prospective studies,OS is beter in PP arm than PD arm.

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.